Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver

Table 7 Comparison of liver pathological findings in the two groups

	DILI (n = 89)	DILI + NAFL (n = 110)	P value
Hepatocellular carcinoma nodule	6 (6.7)	3 (2.7)	0.312
Lipoatrophy	39 (43.8)	77 (70)	0
Brownish-yellow granular deposits	10 (11.2)	13 (11.8)	0.898
Hepatocellular cholestasis	23 (25.8)	45 (40.9)	0.026
Vacuolar degeneration	7 (7.9)	22 (20)	0.016
Spotty necrosis	88 (98.9)	105 (95.5)	0.16
Apoptotic body	61 (68.5)	72 (65.5)	0.646
Inflammatory cell infiltration in the hepatic sinusoids	22 (24.7)	29 (26.4)	0.792
Hepatic sinusoidal dilatation and stasis	1 (1.1)	3 (2.7)	0.769
Pericarditis of the central vein	64 (72.7)	75 (68.2)	0.487
Epithelioid granuloma	2 (2.3)	5 (4.5)	0.636
Bridging necrosis	15 (17)	12 (10.9)	0.211
Phagocytic wax-like deposits	39 (44.3)	34 (30.9)	0.052
Lobular fusion necrosis	1 (1.1)	3 (2.7)	0.778
Expansion of the catchment area	87 (97.8)	107 (97.3)	0.83
Inflammatory cell infiltration in the confluent area	88 (98.9)	107 (97.3)	0.423
Microcystic bile ducts	76 (85.4)	88 (80)	0.32
Interlobular bile duct lesions	4 (4.5)	9 (8.2)	0.461
Boundary board damage	80 (89.9)	91 (82.7)	0.149
Fibrous tissue proliferation	79 (88.8)	105 (95.5)	0.075
Fiber gap formation	1 (1.1)	3 (2.7)	0.769
Lobular structural disorder	1 (1.1)	4 (3.6)	0.502
Iron staining is positive	10 (11.2)	12 (10.9)	0.942
Accompanied by an immune response	26 (29.2)	23 (24.6)	0.176

DILI: Drug-induced liver injury; NAFL: Nonalcoholic fatty liver.